Global Postpartum Depression Market Projected to Grow at 32.5% CAGR, Reaching $49.49 Billion by 2029

Use code ONLINE20 to get 20% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.

What Will the Postpartum Depression Industry Market Size Be by 2025?
The valuation of the postpartum depression market has witnessed dramatic expansion lately, projected to surge from $12.15 billion in 2024 to reach $16.05 billion by 2025, reflecting a rather brisk compound annual growth rate (CAGR) of 32.1%; this upward trajectory throughout the past period is primarily fueled by several factors, including heightened recognition of maternal mental health issues, progress in scientific investigation, governmental and organizational health campaigns, and a rise in routine screening procedures.

What's the Long-Term Growth Forecast for the Postpartum Depression Market Size Through 2029?
Anticipating a period of substantial expansion, the market addressing postpartum depression is projected to surge significantly over the coming years, reaching a valuation of $49.49 billion by 2029, driven by a compound annual growth rate (CAGR) of 32.5%; this accelerated trajectory is fueled by several key factors, including the increasing accessibility of telehealth offerings, breakthroughs in pharmaceutical treatments, new legislative measures supporting maternal mental well-being, and the widening availability of mental health professionals, all while notable industry shifts encompass the adoption of unified care frameworks, the proliferation of peer-to-peer support initiatives, the emergence of mobile applications focused on perinatal mental health, and the greater implementation of mental health assessment instruments.

View the full report here:
https://www.thebusinessresearchcompany.com/report/postpartum-depression-global-market-report

What Are the Key Growth Drivers Fueling the Postpartum Depression Market Expansion?
The projected escalation in instances of postpartum depression is anticipated to serve as the primary catalyst propelling the expansion of the postpartum depression market moving ahead, this condition being characterized by an excessive degree of concern arising subsequent to childbirth, often accompanied by tangible physical manifestations. Furthermore, anxiety following birth frequently overlaps with this depression, and symptom onset can occur at any point within the initial twelve months postpartum, with therapeutic interventions such as psychotherapy, generally termed as counseling or talk therapy, pharmaceutical agents, or an integrated approach involving both modalities, consequently fueling market expansion. For illustration, data from a February 2022 investigation involving 1.1 million mothers, carried out by the University of Virginia School of Medicine (UVA SoM), a medical institution situated in the US, pinpointed that first-time mothers, individuals younger than 25, and those delivering multiples face heightened susceptibility to postpartum depression; specifically concerning age cohorts, the peak self-reported incidence of symptoms stood at 10% among women aged 18 to 24, while mothers of twins exhibited elevated rates of the condition, with 11.3% reporting symptoms versus 8.3% observed in mothers with single infants. Consequently, the growing prevalence of postpartum depression is expected to be the engine of growth for its associated market.

Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=13024&type=smp

What Are the Key Trends Driving Postpartum Depression Market Growth?
Firms engaged within the postpartum depression sector are actively pursuing novel product developments to secure their ongoing market relevance. Scarcity in existing therapeutic options is fueling a growing imperative for innovations centered around agents that offer quicker efficacy and novel modalities for delivering postpartum depression care. A concrete illustration of this drive occurred in February 2023, when US entities Biogen Inc., a biotechnology firm, and Sage Therapeutics Inc., a biopharmaceutical company, disclosed that the United States Food and Drug Administration (FDA) accepted their New Drug Application (NDA) submission for zuranolone, targeting treatment for both major depressive disorder (MDD) and postpartum depression (PPD). Zuranolone represents an investigational agent being evaluated as a swift-acting, oral treatment taken once daily over a two-week span by individuals suffering from MDD and PPD. This neuroactive steroid distinctively functions via positive allosteric modulation of GABA-A receptors. Its anticipated mechanism for mitigating depression involves the rapid recalibration of imbalanced neural circuits, thereby assisting in the restoration of cerebral functionality; specifically, zuranolone influences those brain networks governing emotional state, level of alertness, conduct, and cognitive faculties.

How Is the Postpartum Depression Market Segmented?
The postpartum depressionmarket covered in this report is segmented -

1) By Types: Postpartum Blues; Postpartum Anxiety; Postpartum Obsessive Compulsive Disorder; Postpartum Panic Disorder; Postpartum Post-Traumatic Stress Disorder; Postpartum Psychosis; Other Types
2) By Treatment: Psychotherapy; Medication; Supplements; Other Treatments
3) By Route of Administration: Oral; Parenteral; Other Route Of Administration
4) By Distribution Channel: Hospital Pharmacy; Retail Pharmacy; Online Pharmacy; Other Distribution Channels
5) End-Users: Hospitals; Specialty Clinics; Homecare; Other End-Users

Subsegments:
1) By Postpartum Blues: Mild Emotional Disturbances; Short-term Mood Swings
2) By Postpartum Anxiety: Generalized Anxiety Disorder (GAD); Panic Attacks
3) By Postpartum Obsessive Compulsive Disorder: Intrusive Thoughts; Compulsive Behaviors
4) By Postpartum Panic Disorder: Sudden Panic Attacks; Physical Symptoms
5) By Postpartum Post-Traumatic Stress Disorder (PTSD): Trauma Response To Childbirth; Flashbacks And Anxiety
6) By Postpartum Psychosis: Hallucinations; Severe Mood Swings
7) By Other Types: Mixed Mood Disorders; Comorbid Conditions With Postpartum

Tailor your insights and customize the full report here:
https://www.thebusinessresearchcompany.com/customise?id=13024&type=smp

Which Companies Are Leading the Charge in Postpartum Depression Market Innovation?
Major companies operating in the postpartum depression market are Pfizer Inc., Johnson & Johnson, Roche Holding AG, Merck & Co., AbbVie Inc., Novartis AG, Sanofi SA, Bristol Myers Squibb Co., AstraZeneca PLC, GlaxoSmithKline LLC, Takeda Pharmaceutical Company, Eli Lilly and Company, Gilead Sciences Inc., Amgen Inc., Moderna Inc., BioNTech SE, Viatris Inc., Northwell Health, Teva Pharmaceutical Industries Ltd., Regeneron Pharmaceuticals Inc., Biogen Inc., Vertex Pharmaceuticals Inc., Sun Pharmaceutical Industries Ltd., Lupin Pharmaceuticals, Mallinckrodt Pharmaceuticals PLC, Sage Therapeutics Inc.

Which Regions Are Leading the Global Postpartum Depression Market in Revenue?
North America was the largest region in the postpartum depression market in 2024. The regions covered in postpartum depression market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

Purchase the full report today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=13024

This Report Supports:
1.Business Leaders & Investors - To identify growth opportunities, assess risks, and guide strategic decisions.
2.Manufacturers & Suppliers - To understand market trends, customer demand, and competitive positioning.
3.Policy Makers & Regulators - To track industry developments and align regulatory frameworks.
4.Consultants & Analysts - To support market entry, expansion strategies, and client advisory work.

Reach out to us:
The Business Research Company: https://www.thebusinessresearchcompany.com/,
Americas +1 310-496-7795,
Europe +44 7882 955267,
Asia & Others +44 7882 955267 & +91 8897263534,
Email us at info@tbrc.info.

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Learn More About The Business Research Company
With over 17500+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.Our flagship product, the Global Market Model (GMM), is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.